Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden

Chemotherapy resistance associated with recurrent disease is the major cause of poor survival of ovarian cancer patients. We have recently demonstrated activation of the JAK2/STAT3 pathway and the enhancement of a cancer stem cell (CSC)-like phenotype in ovarian cancer cells treated in vitro with ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Abubaker, Khalid, Luwor, Rodney B., Escalona, Ruth, McNally, Orla, Quinn, Michael A., Thompson, Erik W., Findlay, Jock K., Ahmed, Nuzhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988380/
https://www.ncbi.nlm.nih.gov/pubmed/24782986
http://dx.doi.org/10.3389/fonc.2014.00075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988380/
https://www.ncbi.nlm.nih.gov/pubmed/24782986
http://dx.doi.org/10.3389/fonc.2014.00075

Ejemplares similares